Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 15/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | PRKDC | P78527 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL940811 | 0.88 | MAPT (0.78) | MAPTALDH1A1PKMSMN1; SMN2NPSR1 | |
| SCHEMBL340455 | 0.87 | MAPT (0.78) | MAPTALDH1A1SMN1; SMN2NPSR1MAPK1 | |
| SCHEMBL144859 | 0.86 | MAPT (0.76) | MAPTALDH1A1PKMSMN1; SMN2NPSR1 | |
| SCHEMBL11736626 | 0.86 | MAPT (0.76) | MAPTALDH1A1SMN1; SMN2NPSR1MAPK1 | |
| SCHEMBL1232317 | 0.86 | MAPT (0.75) | MAPTALDH1A1PKMSMN1; SMN2NPSR1 | |
| SCHEMBL5624466 | 0.86 | SIRT6 (0.76) | MAPTALDH1A1PKMSMN1; SMN2NPSR1 | |
| SCHEMBL10743621 | 0.85 | SIRT6 (0.74) | MAPTALDH1A1MAPK1SIRT6 | |
| SCHEMBL19677556 | 0.83 | MAPT (0.70) | MAPTALDH1A1PKMSMN1; SMN2NPSR1 | |
| SCHEMBL18036523 | 0.81 | MAPT (0.75) | MAPTALDH1A1PKMSMN1; SMN2NPSR1 | |
| SCHEMBL7809558 | 0.81 | MAPT (0.67) | MAPTALDH1A1PKMSMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3112348-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Tairx, Inc. (TW) | 2017-01-04 | — | — | EP | disclosed |
| US-8524740-B2 | Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives | TAIRX, INC. (TW) | 2013-09-03 | — | — | US | disclosed |
| EP-2593435-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Tairx, Inc. (TW) | 2013-05-22 | — | — | EP | disclosed |
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Efficient Pharma Management Corporate (TW) | 2012-01-19 | — | — | US | disclosed |
| WO-2012009519-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | EFFICIENT PHARMA MANAGEMENT CORP. (TW) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | SLC22A8, ABCC8, CYP2C8 | MAPT 4760/4885ALDH1A1 1258/4885PKM 4523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.